Tickerover
Healthcare

BIO Stock Analysis

Bio-Rad Laboratories, Inc. · current price $387.77 (-0.48% today)

Top-tier setup — +19% 30-day momentum. Caveat: trades 15.2% above analyst mean target. Stock is trading above the analyst mean target ($329) — limited consensus headroom.
★★★★★
Top Tier
📊

The six-pillar scorecard

Momentum
91
Trending up strong
price trend
Growth
25
Barely growing
sales & profit growth
Quality
88
High quality
profitability & balance sheet
Valuation
0
Expensive
is the price fair?
Sentiment
35
Mixed views
analyst & crowd mood
Risk
73
Low risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
1-month momentum1-month momentum: 9090Relative strengthRelative strength: 100100Trend strengthTrend strength: 100100GrowthGrowth: 4040Breakout proximityBreakout proximity: 7171Earnings accelerationEarnings acceleration: 100100Earnings qualityEarnings quality: 7878
Margin profileWhat survives each step down the income statement.
GrossGross: 52.0%52.0%OperatingOperating: 11.2%11.2%NetNet: 8.6%8.6%Free cash flowFree cash flow: 13.6%13.6%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +50.1% vs estimate+50%2026-062026-03: -4.8% vs estimate-5%2026-032025-12: -7.0% vs estimate-7%2025-122025-09: +17.0% vs estimate+17%2025-09
👁

Hype Check

Reading BIO’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading BIO’s filings…

📣

Latest earnings

LAST EARNINGS Bio-Rad Laboratories, Inc. (BIO)

Latest earnings

EPS
$2.26 vs $1.93 est · +17.0% vs estimate BEAT
Revenue
$651.0M · -0.3% YoY
Stock reaction (1M)
+18.7%
Beat streak
2 of last 4 quarters
💰

Valuation

P/E
47.2×
Forward P/E
38.7×
PEG
4.01
Price / Sales
4.0×
Price / Book
1.4×
EV / EBITDA
22.9×
Analyst target
$329.00
Target range
$280.00 – $390.00
Implied upside
-15.2%
🩺

Financial health

Gross margin
52.0%
Operating margin
11.2%
Net margin
8.6%
FCF margin
13.6%
Return on equity
3.1%
Debt / equity
0.19
Revenue growth YoY
-0.1%
EPS growth YoY
+18.7%
📈

Technicals

$236.7352-week range$396.23
RSI (14)
77
50-day MA
$325.85
200-day MA
$300.23
ATR (14)
10.74
Beta
1.05
1-month return
+18.7%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$2.26$1.93+17.0%Beat
2025-12-31$2.51$2.70-7.0%Miss
2026-03-31$1.89$1.99-4.8%Miss
2026-06-30$2.62$1.75+50.1%Beat
Beat 2 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.00%
Beta
1.05
📰

Latest news on BIO

🔗

Similar stocks in Healthcare

Frequently asked

What is BIO's Quant Score?

Bio-Rad Laboratories, Inc. (BIO) currently has a TickerMover Quant Score of 69/100, rated ★★★★★ Top Tier. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Bio-Rad Laboratories, Inc. (BIO) a buy?

TickerMover does not give buy or sell recommendations. BIO scores 69/100 (★★★★★ Top Tier) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is BIO's score updated?

BIO's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for BIO →